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A B S T R A C T
The process of aging is one of the most complex and intruguing biological phenomenons. Aging is a genetically regu-
lated process in which the organism’s maximum lifespan potential is pre-determined, while the rate of aging is influ-
enced by environmental factors and lifestyle. Considering the complexity of mechanisms involved in the regulation of ag-
ing process, up to this date there isn’t a major, unifying theory which could explain them. As genetic/epigenetic and
environmental factors both inevitably influence the aging process, here we present a review on the genetic and epigenetic
regulation of the most important molecular and cellular mechanisms involved in the process of aging.
Based on the studies on oxidative stress, metabolism, genome stability, epigenetic modifications and cellular senes-
cence in animal models and humans, we give an overview of key genetic and molecular pathways related to aging. As
most of genetic manipulations which influence the aging process also affect reproduction, we discuss aging in humans
as a post-reproductive genetically determined process. After the age of reproductive success, aging countinously pro-
gresses which clinically coincides with the onset of most chronic diseases, cancers and dementions. As evolution shapes
the genomes for reproductive success and not for post-reproductive survival, aging could be defined as a protective mech-
anism which ensures the preservation and progress of species through the modification, trasnmission and improvement
of genetic material.
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Introduction
Over the last century, advances in medicine and bio-
technology, as well as increasing life standard have con-
tributed to a rapid growth of the elderly population. This
increase in the percentage of the elderly has created
many social problems and has become an inevitable
healthcare problem.
The process of aging is one of the most complex and
intruguing biological phenomenons. Aging is usually de-
fined as the progressive and generalized loss of function
resulting in an increasing vulnerability to environmental
factors and growing risk of disease and death1.
Although aging is a widespread process and one of the
most studied biological processes, little is known about
the basic genetic and molecular mechanisms which influ-
ence the process itself, especially in humans. Considering
the complexity of mechanisms involved in the regulation
of aging, up to this date there are more than 300 theories
which are trying to explain them, but none of the theo-
ries provide complete answers2. Theories are usually cat-
egorized into »error« and »program« theories3. The »er-
ror theories« define aging as gradual accumulation of
random molecular damage which leads to deterioration
of physiological functions, phenotypic changes and in-
creased risk for development of various diseases and
death. Oppositely, »program theories« suggest that or-
ganisms are programmed to age and live for a genetically
pre-determined lenght of time4. As the environment and
lifestyle constantly influence genetic changes and epi-
genetic modifications of the genome, the aging theories
inevitably overlap at various levels, and it is impossible
to assort them into strict categories or analyze one cate-
gory with the exclusion of others. Due to these facts, ag-
ing can be defined as a genetically regulated process in
which the organism’s maximum lifespan potential is
pre-determined while the rate of aging is influenced by
environmental factors and lifestyle.
Although aging is under genetic control, it is probably
not programmed in the sense that there are »longevity
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genes« or »gerontogenes« which pre-determine the pro-
cess itself, but rather it is considered that aging is a phys-
iological process which follows embryonic and postnatal
development and is the consequence of a constant inter-
action between the genome and the environment.
Various endogenous and exogenous biological and
chemical stresses, cause damage of macromolecules, in-
cluding DNA, lipids and proteins, which accumulate dur-
ing time. As a result, there is a constant increase in the
vulnerability of the body, leading to a continuously in-
creasing risk of disease and death. Later in life, the bal-
ance between damage and repair, which are mainly un-
der genetic control, becomes crucial for the maintenance
of health as well as development of diseases and aging.
Much of what we know today about the genetics of ag-
ing comes from studies on animal models5. The major
model systems include yeast Saccharomyces cerevisiae,
roundworm Caenorhabditis elegans, fruit fly Drosophila
melanogaster and rodent Mus musculus. Genetic studies
on these models have uncovered numerous genetic path-
ways which regulate metabolism, oxidative stress and
genomic integrity and also influence longevity. These ex-
periments have demonstrated that induced mutations in
various genes which make up a molecular pathway can
dramatically increase lifespan. Although most of these
organisms live much shorter (mice live up to 4 years) and
have distinct physiology than humans, the crucial ge-
netic and molecular pathways are evolutionary conser-
ved across species which makes them a useful basis for
the research on human aging.
Here we present a review on the genetic and epi-
genetic regulation of the most important molecular and
cellular mechanisms involved in the process of aging
based on studies on animal models and humans. As the
environment in which organisms live, including humans,
has critical importance in genome shaping, and as same
genes in different environmental settings lead to differ-
ent phenotypical effects, we also emphasize the impor-
tance of epigenetic modifications in the aging process
and discuss the connection between reproductive ability
and aging.
Genetic Factors Regulating Aging
Although aging and longevity are genetically regu-
lated, the »longevity genes« haven’t been found yet.
However, there are several proposed classes of genes
which influence aging: »longevity assurance genes« which
enhance structure and function of the organism through-
out the life span; »antagonistic pleiotropy alleles« which
enhance reproductive fitness early in the life span, but
have negative effects late in the life span and; »mutation
accumulation« which affects gene structure and changes
phenotypic expression during time6. Aging is most cer-
tainly genetically influenced, but because of the complex-
ity of the human genome and the constant interaction
between the genome and the environment, it is most
likely that there is a polygenic basis for the control of the
rate of aging.
Single gene variations in numerous genetic pathways
have been shown to enhance life span of model organ-
isms. Experimental manipulation of these pathways is
inevitably related to reproductive fitness. For example,
manipulations which mimic adverse environmental con-
ditions also downregulate reproductive activity and pro-
tect the organism during transient environmental chal-
lenges.
1. Oxidative damage
One of the oldest and best studied theories of aging is
»the free radical theory« which supposes that aging re-
sults from the progressive and irreversible accumulation
of molecular damage caused by free radicals. Most biolog-
ically relevant free radicals are generated during oxida-
tive metabolism in mitochondrion and are thus, named
reactive oxygen species (ROS). Long-term exposure to
ROS has deleterious effects on macromolecules including
DNA damage, lipid peroxidation and protein damage and
is reffered to as oxidative stress7. Accumulation of oxida-
tive damage causes dysfunction of organelles, cellular se-
nescence or death and is associated with the develop-
ment of many age-related diseases8.
In multicellular organisms different cell types age at a
different rate. Post-mitotic cells, such as neurons, car-
diac myocytes and skeletal muscle cells are more suscep-
tible to oxidative damage than dividing cells and thus
suffer the most remarkable age-related changes, includ-
ing progressive loss of function and cell death9.
The degree of oxidative stress to the cell is not only
determined by the level of deleterious effects but rather
represents the balance between oxidative damage and
possibilities of cellular defense. One of these mechanisms
includes antioxidantive enzymes, molecules which con-
vert free radicals into energetically stable molecules.
There are two kinds of antioxidants – endogenous, which
are generated in the organism (superoxide dismutase,
catalase, peroxidases) and exogenous (vitamins C and E,
b-carotene, coenzyme Q10, selenium)8.
Genetic regulation of oxidative damage
The rate of aging could be affected by differences in
genetically controlled resistance to oxidative stress. Ge-
netic manipulations which increase oxidative damage
shorten lifespan, while those which lead to increased re-
sistance to oxidative damage, extend it. The majority of
studies on oxidative damage include manipulations of
genes encoding for antioxidative enzymes and enzymes
involved in mitochondrial oxidative metabolism. As most
of these genes are evolutionary conserved across species,
studies on animal models might provide insights into
how these mechanisms are involved in the regulation of
human aging.
These studies have also shown that extension of life-
span as well as premature aging in models from yeast to
mice support the association between metabolic rate, oxi-
dative metabolism, stress resistance and aging10. This is
known as the »rate of living theory« which states that
the metabolic rate of a species determines its life expec-
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tancy is closely related to the »free radical theory«.
Higher metabolic rates often result in shorter lifespan
partly due to the increased production of free radicals11.
C. elegans. Mutational inactivation of several mito-
chondrial genes, such as the clk-1 gene which encodes a
mitochondrial protein involved in the synthesis of ubi-
quinone, increases longevity by 15–35% and induces re-
sistance to oxidative stress12. This gene is part of the
»clock group of genes« which are evolutionary conserved
in many species and mutations in these genes reduce the
rate of metabolism, lead to decreased ROS production
and slower accumulation of damage13. Also, mutations
which impair the expression of genes which encode the
subunit of the succinate dehydrogenase and a cytosolic
catalase, the mev-1 and ctl-1 gene, respectively, reduce
lifespan. Mutants with impaired mev-1 functions also
have reduced SOD activity and are hypersensitive to
oxygen14.
D. melanogaster. Overexpression of the SOD1 (CuZn-
-SOD), SOD2 (Mn-SOD) and cat genes which encode for
copper/zinc and manganese superoxide dismutases and
catalase antioxidants, respectively, increases the lifespan
of transgenic D.melanogaster by 34% and makes them
highly resistant to oxidative stress15.
Overexpression of the Methuselah (Mth) gene encod-
ing the G protein–coupled receptor (GPCR), which is ho-
mologous to a mammalian family of peptide hormone re-
ceptors, increases longevity of D.melanogaster by 35%.
Although its exact function is not known, these animals
become resistant to oxidative stress, heat and starva-
tion16. Flies with mutations in the stunted gene which
encodes ligands of Mth show increased lifespan and resis-
tance to stress17.
M. musculus. Certain genetic interventions which ex-
tend life expectancy in invertebrates do not have the
same effect in mice18. Mice knocked out for glutathione
peroxidase (GPX1) gene do not show signs of rapid aging
but develop multiple age-related diseases and die prema-
turely19. Disruption of the mitochondrial form of super-
oxide dysmutase 2 (SOD2) gene is lethal due to neurode-
generation and dilated cardiomyopathy20,21. In contrast,
overexpression of the catalase and SOD2 genes increases
lifespan22.
The association between calorie intake, rate of metab-
olism and the production of ROS has also been observed
in mice. Deletion of Shc gene encoding the p66shc pro-
tein, an important regulator of cellular redox potential
and oxidative damage in response to extracellular sig-
nals, including insulin, reduces production of ROS, in-
creases resistance to oxidative stress–induced apoptosis,
delays aging and increases longevity by 30%23. p66Shc
knockout mice are also protected against vascular, car-
diac, and renal diseases attributable to hypercholesterol-
emia, diabetes and aging24.
Humans. The association between genes regulating
oxidative stress and human aging has been studied to a
much lesser extent than in animal models. The exact role
of polymorphisms in genes encoding for antioxidants is
not known. Up to this date there are only a few studies
which have associated SOD2 genetic variations with can-
cer, immunosenescence and DNA damage but not with
lifespann25. Thus, the exact role of these genetic factors
in human longevity remains to be elucidated.
Alterations in the intracellular redox state activates
several stress-acting pathways, including phosphatidyli-
nositol-3-OH kinase (PI3K)/Akt, ERK (extracellular sig-
nal-regulated kinase), cJun, MAPK (mitogen-activated
protein kinase), NFkB (nuclear factor kappa B) and p53,
which then alter the expression of target genes to pro-
vide a pro-survival signal during oxidative stress26. These
pathways are also involved in the processes of normal
growth, metabolism and cell signaling.
It has recently been shown that the Raf/MEK/ERK
and PI3K/Akt signalling pathways which are essential
for cellular proliferation, are down regulated in the nuclei
of senescent cells resulting in decreased cell survival26.
2. Metabolism and aging
The rate of metabolism and various dietary factors
have a profound effect on numerous aspects of health
and aging. Calorie restriction (CR) (the diet which con-
tains all essential nutrients but is restricted in calories
by 30–40% compared to animals fed ad libitum) not only
increases longevity but also postpones age-related dis-
eases, such as cardiovascular diseases, diabetes and can-
cer27,28. The maintenance of homeostasis throughout an
organism’s life span requires constant adaptation to chan-
ges in energy levels. The limitation of food intake with-
out malnutrition increases longevity and postpones ag-
ing in all tested model organisms29,30, but the exact
mechanism by which CR influences aging is not known.
It is supposed that CR reduces metabolic rate, decreases
the production of ROS and induces resistance to various
forms of stress11. Nutritional factors have a profound in-
fluence on genetic material and CR alters the level of ex-
pression of many genes, regulates transcription factors
and modulates epigenetic modifications31 and genetic in-
terventions in genes involved in signalling pathways
which respond to nutrient status have been shown to af-
fect aging and longevity.
Insulin/insulin-like growth factor 1 signalling
pathway
Calorie intake and diet are closely related to endo-
crine system. The insulin/insulin-like growth factor 1
(Ins/Igf-1) is the best characterized signalling pathway
which regulates the response to glucose. Organisms with
genetic manipulations in Ins/Igf-1 pathway develop a
phenotype similar to CR, exhibit changes in glucose me-
tabolism and have significantly extended lifespan32. This
pathway is conserved in C.elegans, D.melnogaster, M.
musculus and humans and regulates the activity of FOXO
transcription factors which activate antioxidantive en-
zymes, heat shock proteins, metabolic genes, protein kin-
ases and many others33,34. All of these long-lived mutants
show certain similarities, such as low levels of circulating
Igf-1, low plasma insulin and glucose levels, increased
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tissue sensitivity to insulin, reduced production of ROS
and resistance to heat and oxidative stress35. As Ins/Igf-1
pathway is involved in the regulation of metabolism,
growth and reproduction, genetic interventions which
increase lifespan also affect these functions.
C. elegans. The Ins/Igf-1 signalling pathway in C.ele-
gans consists of proteins encoded by daf-2, age-1 (daf-26),
akt-1, akt-2, daf12, daf-16 and daf-18 genes. These genes
are part of the »dauer formation« (daf) group of genes
which regulate reproduction and the shift from a normal
metabolic state to a metabolically inactive state, known
as the »dauer larva« formation.
The first longevity mutant to be identified was the
Age-1 gene, which encondes a homologue of mammalian
PI3K36. Age-1 mutants have a slower metabolic rate, dis-
play age-dependent elevations of copper/zinc superoxide
dismutase (CuZn-SOD) and catalase, are resistant to oxi-
dative stress and live 65% longer.
The main gene of the Ins/Igf-1 cascade is the daf-2
gene which encodes an insulin-like receptor protein (DAF2)
homologous to the separate insulin and Igf-1 receptors in
vertebrates. Mutations which decrease the level of daf-2
gene expression extend lifespan37.
Genes encoding insulin-like proteins which bind to
DAF2 and modulate metabolic response, are found in
chemosensory neurons and are released in response to
food sensing38. Worms with defects in chemosensory neu-
rons show increase in lifespan up to 121%.
The inhibition of Ins/Igf-1 signalling pathway, i.e. the
reduced insulin signalling, as well as CR, in C.elegans re-
duces fertility and increases lifespan possibly to delay re-
production until the period of limited food ends. These
mutants have a slower metabolism, increased resistance
to oxidative stress and express high levels of catalase and
SOD, which shows that CR and the production of free
radicals are related.
D. melanogaster. Genes involved in the Ins/Igf-1 sig-
nalling pathway in D.melanogaster show high homology
with those in C.elegans. Decreased expression of the Inr
(insulin receptor) gene which encodes the Ins/Igf-1 recep-
tor (homologue of C.elegans DAF2r and human insulin
and Igf-1 receptor) and the chico gene (Inr substrate) in-
crease lifespan in females by 85% and 52%, respecti-
vely39,40. Both chico and Inr mutant adults are sterile
which proves that Ins/Igf-1 regulates fertility and life-
span in response to nutrition. These long-lived mutants
have reduced insulin signalling, increased levels of SOD
and tryglycerids and reduced body size40.
M. musculus. In mammals, the Ins/Igf-1 signalling
pathway is more complex and contains separate recep-
tors for insulin and Igf-1. Mutations of Prop-1 (pro-
phet-of-Pit-1) and Pit-1 (pituitary-specific transcription
factor 1) genes, which encode transcription factors in-
volved in pituitary development, are known to extend
lifespan. Ames and Snell dwarf mice are knockouts for
Prop-1 and Pit-1 genes, respectively, and both have pitu-
itary agenesis resulting in panhypopituitarism, short
stature and infertility41. The lifespan of Ames mice is ex-
tended by 50% in females and 64% in males, while the
lifespan of Snell mice is extended by 40% in both sexes42.
The extended lifespan is thought to be the consequence
of growth hormone (GH) and subsequently, Igf-1 defi-
ciency. In the lack of GH and Igf-1 insulin release is re-
duces, tissue sensitivity to insulin increased and plasma
glucose levels lowered41. A similar phenotype is observed
for GH receptor knockout mice43.
Dwarf mice with high levels of GH along with 90%
lower levels of Igf-1 live longer than wild-type mice which
indicates that low levels of Igf-1 but not GH are responsi-
ble for an extended lifespan43. Additional evidence that
Igf-1 is responsible for increased lifespan comes from
heterozygous Igf-1r knockout mice which show insensi-
tivity to Igf-1 and 26% longer lifespan44. Thus, lifespan
can be extended by either low levels of circulating Igf-1 or
a general decrease in Igf-1 receptor levels.
Disruption of specific insulin receptor in adipose tis-
sue extends longevity by 134 days (18%) in FIRKO (fat-
-specific insulin receptor knock-out) mice45. These mice
have normal calorie intake but are protected from age-re-
lated obesity because the lack of insulin receptor in adi-
pose tissue leads to absence of insulin signalling, reduces
the transport of glucosis and aminoacids and impairs
their conversion to fat which leads to decreased body
mass. Adypocytes of FIRKO mice produce increased lev-
els of leptins, which stimulate the hypothalamus to the
production of metabolites which decrease calorie intake,
increase energy expediture and decrease insulin pro-
duction46. Mutations in the leptin gene, Lep, causes down-
regulation of TOR (target of rapamycin) signalling, hy-
perphagia and massive obesity, along with decreased life-
span.
Klotho gene, which was identified in mouse models,
encodes the klotho transmembrane protein homologous
to mammalian lactase glycosylceramidase. Klotho is in-
volved in glucosis metabolism through negative regula-
tion of insulin and Igf-1 receptors and also regulates cal-
cium metabolism47. Overexpression of klotho gene inhibits
Ins/Igf-1 signalling pathway in mice, increases resistance
to oxidative stress through the induction of SOD and ex-
tends lifespan. Disruption of klotho gene leads to de-
creased lifespan and premature onset of age-related dis-
eases such as osteopenia and atherosclerosis48. The homo-
logy of klotho with mammalian lactase glycosylceramidase
suggests that klotho might regulate sphingolipid metab-
olism whose products regulate cell cycle, replicative se-
nescence and apoptosis. Recent studies have shown that
homozygous KL-VS allele carriers have lower levels of
high-density lipoprotein (HDL), higher systolic blood pre-
ssure, increased risk of stroke and shorter longevity49.
Humans. In humans, patients with defect in the
GH/Igf-1 axis have various health problems. Patients
with Laron syndrome, an autosomal recessive disease
caused by GH insentivity due to GH receptor gene muta-
tion, have various medical problems but show increased
lifespan and live up to 90 years of age50.
Although the influence of Ins/Igf-1 signalling pathway
on longevity in humans hasn’t been well studied, there is
S. Ostoji} et al.: Genetics and Epigenetics of Aging, Coll. Antropol. 33 (2009) 2: 687–699
690
some evidence that it is involved in the aging process.
Long-lived people and centenerians have increased tissue
sensitivity to insulin, lower levels of circulating Igf-1 and
preserved insulin action51. Decreased Igf-1 plasma levels
probably reduce cellular proliferation and decrease the
risk of cancerogenesis. It has been shown that centenari-
ans have Igf-1r gene polymorphisms which are associ-
ated with lower plasma levels of Igf-152.
Cholesterol metabolism in humans. The most com-
mon age-related conditions have important nutritional
components, such as cardiovascular diseases, diabetes,
stroke, osteoporosis, cataract, and cognitive decline53.
Susceptibility genes for human diseases also influence the
aging process and genes involved in the pathogenesis of
cardiovascular diseases seem to be a crucial determinant
of human lonevity. The metabolism of lipoproteins and
cholesterol influences longevity, and individuals with ex-
ceptional longevity have significantly larger HDL and
LDL particle sizes54. This is associated with lower inci-
dence of hypertension and cardiovascular diseases. Also,
certain genotypes of apolipoprotein E (apoE), influence
lifespan through association with disease55.
The a and b liver-X-receptors (LRX) are most similar
to C.elegans daf-12 nuclear hormone receptor which reg-
ulates fertility and metabolism. In humans, the LRX reg-
ulate cholesterol metabolism. Certain polymorphisms are
associated with increased lifespan and show protective
effect from cardiovascular diseases56.
In general, many benefits of CR are accompanied by a
number of negative effects, especially delayed growth
and changes in fertility, which makes it unsuitable for re-
search in humans. It is well known that eating disorders,
as in case of increased calorie intake, lead to obesity and
premature onset of multiple disorders such as athero-
sclerosis, diabetes and cardiovascular diseases, while mal-
nutrition as in case of anorexia nervosa leads to ano-
vulation and secondary sterility53.
Forkhead transcription factors (FOXO)
FOXO proteins are a subgroup of the Forkhead family
of transcription factors and regulate tumor suppression,
energy metabolism, and longevity. FOXO factors are key
downstream targets of insulin, growth factors, nutrient,
and oxidative stress stimuli and control numerous cellu-
lar functions57. In invertebrates, there is only one FOXO
gene (daf-16 in C.elegans, dFOXO in D.melanogaster)
and four FOXO genes in mammals (FOXO1a, 3a, 4, 6).
FOXO-dependent cellular responses include gluconeo-
genesis, neuropeptide secretion, atrophy, autophagy, apo-
ptosis, cell cycle arrest, and stress resistance57.
C. elegans. In response to insulin-like proteins, Daf-2
activates age-1 protein and leads to phosphorylation of a
cascade of enzymes which ultimately regulate the nuclear
translocation of daf-1658. The long-lived mutants have an
active daf-16 protein. As the Ins/Igf-1 signalling pathway
negatively regulates the activity of DAF-16, in the ab-
sence of insulin-like proteins, daf-16 is located in the nu-
cleus where it induces expression of target genes in-
volved in the induction of heat and stress resistance, fat
storage, development arrest, fertility and metabolism59.
Humans. Mammalian FOXO proteins, the target fac-
tors of Ins/Igf-1 signalling pathway, are phosphorylated
and inhibited in response to insulin and growth factor
stimulation60. FOXO target genes regulate glucose me-
tabolism, cellular differentiation and energy consumption.
Certain gene polymorphisms in FOXO1a and FOXO3a
genes have been associated with higher glucose levels, in-
creased risk of diabetes, the incidence of age-related dis-
eases and shorter lifespan61. FOXO3a enhances the ex-
pression of the MnSOD and catalase antioxidant enzymes
and is also an important sensor for cellular stresses, such
as cytotoxic stress.
AMP-activated protein kinase. Recently, a lot of atten-
tion is paid to the AMP-activated protein kinase as a life-
span gene. AMPK is activated by a decrease in energy
levels when it inactivates energy consumption pathways
and activates energy production pathways. For instance,
metabolic stresses which increase the cellular AMP:ATP
ratio (such as hypoglycemia) activate the AMP Kinase
(AMPK) system. AMPK protects cells against stresses by
activating alternative metabolic pathways and inhibiting
cell growth and division. AMPK directly regulates FOXO3,
which then promotes resistance to oxidative stress and
longevity and control energy balance and stress resis-
tance in cells throughout life62.
TOR signalling pathway
The target of rapamycin (TOR) proteins are an evolu-
tionary conserved part of a protein family termed the
phosphatidylinositol kinase-related kinases (or PIKKs),
a large group of signaling molecules which function as
Serine/Threonine protein kinases. The TOR regulates
cell growth and metabolism in response to environmen-
tal stimuli. It integrates signals which coordinate cell
growth, cell proliferation, cell motility, survival and cell
cycle progression with sufficiency of nutrients, energy,
and growth factors63. TOR signaling pathway is also a
sensor of cellular redox status and regulates mitochon-
drial homeostasis and gene expression.
Various forms of stress and nutrient deprivation re-
duce TOR signaling which then stimulates CR, energy
saving and leads to increased longevity. There is also a
functional link between TOR and Ins/Igf-1 signalling
pathway in worms, flies and mammals.
S. cerevisiae. Deletion of the Tor1 gene extends chro-
nological life span primarily by increasing mitochondrial
respiration via enhanced translation of mtDNA-encoded
oxidative phosphorylation complex subunits64. Tor1 also
interacts with Sch9 (AKT homologue) and PKA (pro-
tein-kinase A) proteins and regulates cellular response to
altered glucose and nitrogen levels65. Inhibition of Tor1,
Sch9 and PKA activity increases lifespan, reduces stress
response and transcription of ribosomal proteins by rDNA
(ribosomal DNA) silencing.
C. elegans. Disruption of TOR and its regulatory pro-
tein Raptor causes developmental arrest, intestinal atro-
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phy and increased lifespan66. The Raptor protein is en-
coded by Daf-15 gene which is regulated by Daf-16.
Although this increase in lifespan is independent of Daf-16,
these results indicate that there is a cross-talk between
TOR and Ins/Igf-1 signalling pathways which converge
on Daf-15 to regulate larval development, metabolism
and life span. Both of these pathways integrate nutrient
sensing, calorie intake and influence longevity.
Mammals. Mammalian TOR (mTOR) is one of the
most intruguing pathways associated with aging. This
pathway regulates embryonic growth and development
in response to nutrients and is also involved in the
pathogenesis of numerous disease, indicating that aging
and embryonic development share similar executive me-
chanisms. The mTOR integrates the signals from multi-
ple upstream pathways, including insulin, insulin-like
growth factors (Igf-1 and Igf-2), and mitogens.
Mice with disruption of mTOR die shortly after im-
plantation due to impaired cell proliferation in embry-
onic and extraembryonic tissues67. The dysregulation of
the mTOR pathway is implicated as a contributing factor
to cancer, diabetes, obesity, cardiovascular diseases and
neurological disorders68. Although the exact role of mTOR
on longevity remains to be discovered, the fact that
mTOR is associated with the onset of many age-related
diseases indicated that research on this pathway may
bring many key answers to aging process in mammals.
3. Genomic stability
Considering that DNA is continuously damaged by
endogenous and exogenous agents and by intrinsic insta-
bility of chemical bonds within DNA, genomic instability
is a crucial component of aging in all organisms. Genomic
instability affects gene expression and protein produc-
tion which can lead to cell death, cancer, various diseases,
and overall functional decline68. Proposed mechanisms
which affect the process of aging through genomic insta-
bility include DNA mutations, damage to cellular compo-
nents, inefficient DNA repair and epigenetic mechanisms.
DNA damage
Point mutations, chromosome aberrations, mitotic re-
combination and other forms of DNA damage increase
with aging in both invertebrates and vertebrates which
makes cumulative damage to the nuclear and mitochon-
drial DNA one of the main causes of aging. Extensive
DNA damage which cannot be repaired or which canges
DNA metabolism leads to cellular sensescence or death.
Numerous factors cause DNA damage, include exoge-
nous (radiation, stress, and toxins) and endogenous fac-
tors (ROS, replication errors and chemical changes to the
DNA). During aging all cells accumulate mutations, in-
cluding the germline and it is well known that increasing
parental age is the single most important risk factor for
aneuploidic conceptions and miscarriage69.
Although the somatic mutation theory supposes ran-
dom damage, genes like HLA, repetitive and telomere se-
quences accumulate damage 2–3x faster than other ge-
nes70. Accumulation of DNA damage can result in loss of
cellular and tissue functions through a combination of
energy insufficiency, signalling defects, apoptosis, repli-
cative senescence and aberrant gene expression which
can in turn lead to many diseases and cancers.
As ROS are a source of chronic, peristant DNA dam-
age, aging cells and organisms accumulate increased lev-
els of oxidant-damaged nuclear and mitochondrial DNA
(mtDNA). Oxidative damage to mtDNA is up to 20x
higher than to nuclear DNA, due to its proximity to the
source of oxidant generation, the fact that it lacks protec-
tive histone proteins and has a limited DNA repair sys-
tem. In humans, mtDNA accumulates mutations pro-
gressively and there is also age-related decrease in the
respiratory chain capacity in various tissues. Post-mi-
totic cells, are especially sensitive to the loss of mtDNA
integrity which leads to mitochondrial functional decline
and oxidative stress and might also contribute to devel-
opment of Alzheimer’s disease71. Certain mtDNA haplo-
types are more common in centenerians and the degree
of age-induced mutation in mtDNA varies among indi-
viduals indicating that the rate of aging might be influ-
enced by the genetic structure of mtDNA.
DNA repair system
DNA repair system is needed for maintaining the in-
tact structure and function of DNA as well as for ensur-
ing genomic stability. During aging, the ability of DNA
repair system decreases along with the accumulation of
DNA damage68.
p53. The p53 tumor-suppressor gene is one of the
most important genes implicated in the maintenance of
genomic stability and has a crucial role in cellular re-
sponses to DNA damage. It is also called »cancer gene«
due to its inactivation in over 80% of cancer72. In re-
sponse to stress signals, p53 becomes functionally active
and induces either a transient cell cycle arrest, apoptosis
or cellular senescence.
Studies on mouse models indicate association between
the tumor suppressive and age-promoting functions of
p5372. Overexpression of p53 gene in mice decreases can-
cer incidence but these mice live shorter and show signs
of premature aging. Several recent studies have shown
that the common Arg72Pro polymorphism of p53 gene is
associated with increased longevity and cancer survival
in humans73.
WRN Helicase. There are several human premature
aging syndromes which include defects in the nuclear
DNA repair system, such as Xeroderma pigmentosum
(XP), Werner, Bloom and Cockayne syndrome. WRN and
BLM genes encode RecQ-like helicases involved in the
nucleotide excision repair (NER) and telomere mainte-
nance. Werner syndrome cells exhibit premature repli-
cative senescence, defects in recombination, increased
DNA damage and reduced DNA repair which leads to
genomic instability and premature aging phenotypes74.
WRN protein is also an exonuclease and plays significant
roles in DNA replication and telomere maintenance.
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Nuclear lamina
An important factor involved in maintaining the ge-
nomic stability in human cells is the structure of nuclear
lamina and nuclear morphology. Nuclear Lamin proteins
which build up the nuclear lamina regulate several nu-
clear processes such as transcription, chromatin organi-
zation and DNA replication, and maintain nuclear and
cellular integrity75. Mutations in the LMNA gene, encod-
ing A-type lamins, lead to cardiac and skeletal muscle
disease, lipodystrophy and several premature ageing syn-
dromes. LMNA defective cells show nuclear deformation,
relocalization of heterochromatin and an upregulated
DNA damage response.
Ribosomal DNA
Loss of genomic ribosomal DNA (rDNA) has been as-
sociated with cellular and organismal ageing. The rDNA
genetic locus occupies a large part of the genome and
thus, the condition of the rDNA, such as its stability,
might affect cellular functions76.
Aging in S.cerevisiae is determined by the replicative
lifespan, i.e. the number of times an individual cell di-
vides77. Studies on aging in S.cerevisiae have shown that
aging is a result of progressive disregulation of the rDNA
locus. The rDNA locus contains 100–200 tandem repeats
of genes encoding rRNA which organize the nucleolus.
During aging the production of rRNA increases, leads to
the assembly of defective ribosomes and inefficient pro-
tein synthesis77.
Homologous recombination of rDNA leads to forma-
tion of extrachromosomal rDNA circles (ERCs) which ac-
cumulate during each cell division up to a 1000 copies per
mother cell78. Accumulation of these ERCs causes geno-
mic instability and is one of the major causes of aging in
yeast.
There has been some association between rDNA and
aging in humans. It has been recently shown that during
ageing a preferential loss of 5S and 28S rDNA genes can
be seen in human adipose tissue79.
Epigenetic Mechanisms and Aging
Epigenetics is the study of heritable and reversible
changes in gene expression that occur without a change
in DNA sequence. Epigenetic mechanisms, such as DNA
methylation, histone modifications, chromatin remodel-
ing, asynchronus DNA replication, and regulatory non-
-coding RNAs enable precise regulation of gene expres-
sion dependent on cell type and developmental period.
Epigenetic modifications represent the link through which
the environment interacts with the genome and modu-
lates gene expression in response to external factors,
such as diet and various stresses. Each differentiated cell
type has its own epigenetic signature, which reflects ge-
notype, developmental history, and environmental influ-
ences and ultimately reflects the phenotype of the cell
and organism80.
Histone modifications, as well as DNA methylation
and probably other epigenetic modifications respond to
metabolic state of the cell and other environmental stim-
uli, including stress.
Studies of twins and longlived families have esti-
mated that 20–30% of the variation in human lifespan is
determined by genetic factors, which impact becomes
more important for survival at older ages. Monozygous
twins exhibit remarkable differences in the overall con-
tent of DNA methylation and histone acetylation which
affects their gene expression and leads to different phe-
notypes81. These data provide evidence that epigenetic
variations during aging can also occur independently of
the genetic sequence. This phenomenon is known as
»epigenetic drift« and is attributed to the effect of differ-
ent environments on the same genomic sequences.
During early embryonic development the genome of
eutherian mammals undergoes dramatic changes in epi-
genetic mdifications in order to ensure proper differen-
tiation82. After the completion of organogenesis, these
modifications are stably maintained during each cell di-
vision. However, the genome is not a static structure, but
rather goes through a lifelong remodelling that specifies
and modulates expression of various genes which deter-
mine organism functions in relation to life period. Dur-
ing postnatal life, epigenetic modifications are not fixed,
but are constantly changing, either in response to envi-
ronmental stimuli either spontaneously. Thus, aging is
part of the normal ontogenesis which follows embryonic
and postnatal development and is indeed genetically de-
termined, i.e. the consequence of extensive continuous
genetic/epigenetic changes.
Considering that the epigenetics of aging involves
complex and extensive mechanisms, here we will give
only a brief overview on the impact of DNA methylation
and histone modifications on the aging process.
1. DNA methylation
DNA methylation, the addition of a methyl group to 5
position of cytosine pyrimidine ring, in adult somatic tis-
sues, typically occurs in a CpG dinucleotide context (re-
gions of DNA where a cytosine nucleotide occurs next to
a guanine nucleotide and are separated by a phosphate
which links the two nucleosides together in the DNA).
During aging somatic cells undergo alterations in the
amount and pattern of DNA methylation on the global
and tissue-specific level.
Global DNA methylation decreases during aging in
various cell types83. Although the exact cause and mecha-
nism by which this global hypomethylation occurs re-
mains unknown, one of the reasons might be the pro-
gressive decline in DNA methyltransferase 1 (Dnmt1)
activity which leads to passive demethylation. Global
hypomethylation of genomic DNA is a common charac-
teristic of aging and cancerogenesis, which indicates that
accumulation of epigenetic alterations might be an im-
portant factor for neoplastic transformation84.
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Age-related methylation changes also occur in a tis-
sue-specific manner and include gene promoters, as well
as noncoding DNA sequences. Gene promoters rich with
CpG islands become hypermethylated during aging, most
likely as a consequence of increased Dnmt3b de novo
methylation activity85. Hypermethylation of estrogen re-
ceptor promoter in cardiovascular system with increas-
ing age may play a role in atherogenesis and aging of the
cardiovascular system86.
Another example of promoter hypermethylation in-
volves the Insulin-like growth factor 2 gene (Igf-2) which
is a genomically imprinted gene expressed only from pa-
ternal allele and encodes the major fetal growth factor.
During aging, the Igf2 promoter methylation becomes
more extensive and spreads on the paternal allele, result-
ing in biallelic promoter methylation which can lead to
aberrant Igf-2 expression87. High levels of Igf-2 increase
the risk of cancer and accelerate development of athero-
sclerosis and numerous age-related diseases. As previous
studies indicate, genetic variations which regulate epi-
genetic mechanisms during development are also impor-
tant determinants of aging process. We have shown that
SNPs in Igf-2 gene are crucial for embryonic develop-
ment and successful pregnancy outcome88. Several Igf-2
genotypes are associated with the rate of aging through
population studies. As Igf-2 has a crucial role in embry-
onic development and as it shows dramatic DNA me-
thylation changes during aging, it could be one of the
most important determinants of the aging process, espe-
cially because of its role in the pathogenesis of age-re-
lated diseases. Thus, future studies are needed to further
evaluate the role of Igf2 in aging.
The loss of epigenetic control, in sense of global hypo-
methylation as well as promoter hypermethylation, al-
ters gene expression and leads to genomic instability
which in turn promotes cell senescence, death or can-
cerogenesis. Age-dependent methylation and histone mo-
difications changes are also involved in the development
of several age-related diseases such as neurologic disorders,
autoimmunity and cancer89. These progressive changes
in DNA methylation were proposed to be a cellular
counting mechanism which triggers senescence90. Along
with embryonic downregulation of telomerase, alterations
in DNA methylation pattern during aging could be a ge-
netically determined »post-embryonic counting« mecha-
nism, a »time-bomb« which is set after fertilization and
dictates lifespan thereafter.
Fetal programming. Interindividual variations in DNA
methylation patterns occur due to alterations in diet, ge-
netic polymorphisms, lifestyle exposures and various en-
vironmental factors. Diet has been shown to dynamically
affect DNA methylation status. For example, folate is in-
volved in the synthesis of SAM (S-adenosyl-methionine),
the universal methyl donor, and thus, changes in folate
sources can lead to aberrant DNA methylation. DNA
methylation is essential for early embryonic develop-
ment and folate deficient diet, as well as certain poly-
morphisms in genes involved in folate metabolism, have
been implicated in neural tube defects, Down’s syndrome
and numerous pregnancy complications, including recur-
rent spontaneous abortion91.
Considering the critical roles that epigenetic modifi-
cations play in mammalian growth and development,
early nutritional influences on these components could
have an important role in human health92. Prenatal and
early postnatal nutritional influences on epigenetic gene
regulation represent a link between early nutrition and
later metabolism and susceptibility to age-related dis-
eases including cardiovascular diseases, type 2 diabetes,
obesity, and cancer93,94. This phenomenon is called »fetal
programming« and again points to the fact that there is a
link between nutrition, embryonic development and ag-
ing and that these are not separate processes but rather
different stages of the same developmental process.
2. Histone modifications
Modifications to N-terminal tails of histone proteins
(acetylation, deacetlyation, ubiquitination etc), which can
lead to chromatin remodelling, are sufficient to regulate
gene expression levels and epigenetically alter gene func-
tioning. Epigenetic regulation through histone modifica-
tions might be an important regulator of the cellular se-
nescence phenotype.
Since the discovery of Sirtuins and epigenetic regula-
tion of telomeres, it has become clear that chromatin re-
modeling plays an important role in aging and cellular
senescence.
Telomeres and cellular senescence
Cellular senescence is the process which limits the
number of cell divisions and results in irreversible cell
cycle arrest with characteristic morphologic and func-
tional alterations of the cell95. This replicative limit is
also known as »Hayflick phenomenon or limit«. There
are two kinds of cellular senescence, replicative and
stress-induced premature senescence (SIPS).
Replicative senescence results from the progressive
shortnening of telomeres, the specialized chromatin struct-
ures composed of repetitive DNA sequences (TTAGGG)
and binding proteins which are located at the ends of
chromosomes and serve to protect these areas from re-
combination, fusion and degradation. During each cell
division telomeres continuously lose TTAGGG repeats
because DNA polymerase cannot extend the linear ends
of DNA molecule. This progressive telomere shortnening
represents a form of »genetically determined molecular
clock« which determines cellular senescence and death96.
Telomerase, the enzyme which maintains telomere len-
ght by adding telomeric repeats, is expressed only in the
most proliferative cells such as trophoblast cells, germ
line cells, embryonic stem cells, lymphocytes, skin and
intestine epithelium and hair follicle cells.
It is likely that replicative senescence is a form of pre-
vention from genomic instability and cancerogenesis in
aged cells. The GGG triplets represent sites of frequent
oxidative damage which provides protection against da-
mage to other areas in the genome, but at the same time
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this also increases the rate of telomere shortening and
aging97. Post-mitotic cells with high metabolic rates and
increased oxidative stress, such as cardiomyocytes, ex-
press telomerase which protects telomeres and promotes
survival98. Approximately 90% of all tumors upregulate
telomerase which helps the cells to overcome a limited
proliferative capacity and become immortalized due to
the bypass of cellular arrest.
Mouse models have been crucial for the understand-
ing of the basic molecular mechanisms of telomere func-
tion in aging and age-related diseases. Late-generation of
mice deficient for Terc gene, which encodes a telomerase
RNA component, show progressive telomere shortening,
have shortened lifespan and develop numerous age-re-
lated diseases, including heart failure, immunosenescence,
tissue atrophies and sterility99.
Similar to this, in humans, short telomeres are associ-
ated with many age-related diseases, such as coronary
atherosclerosis, vascular demention and Alzheimer’s di-
sease100. Humans with shorter telomeres have worse sur-
vival and increased mortality from heart and infectious
disease.
It seems that short telomeres represent a form of
DNA damage which influences the loss of cell viability. In
mice which lack telomerase, short telomeres upregulate
p53 tumor-suppressor gene, a crucial mediator of cellular
response to DNA damage, which induces apoptosis and
protects from further damage and cancerogenesis101. Te-
lomerase and p53-deficient mice have suppressed aging
phenotype but develop an increased number of carcino-
mas which indicates that short telomeres contribute to
genomic instability102.
Several human premature aging syndromes are char-
acterized by a faster rate of telomere shortening due to
mutations in genes involved in the regulation of telomere
state103. One of these syndromes includes dyskeratosis
congenita (DC) which is caused by mutations in genes
encoding for components of the telomerase complex. Mu-
tations affect either the Terc or Tert gene encoding the
RNA and enzymatic components of telomerase, respec-
tively, or DKCN1 gene which encodes dyskerin, a protein
involved in rRNA processing, ribosome biogenesis and
Terc stability. Patients with DC have increased risk of
cancerogenesis and develop multiple pathologies similar
to those seen in telomerase-deficient mice which are the
consequence of defects in telomerase activity, telomere
shortening and genomic instability104.
Stress-induced premature senescence (SIPS). SIPS oc-
curs in response to numerous environmental stressors
(ionizing radiation, free radicals, ethanol, DNA damage
etc) and prematurely induces the same phenotypes as
replicative senescence prior to Hayflick limit105. These
adverse factors lead to telomere shortening, negatively
impact telomerase activity and activate p53 gene which
induces apoptosis. SIPS protects from genomic instabil-
ity induced by DNA damage and is most likely the molec-
ular response to cumulative damage during aging.
Other epigenetic factors regulating telomere shorten-
ing. It seems that not only the telomere lenght but also
overall telomere structure is important in cellular senes-
cence. The NAD+-dependent histone H3K9 deacetylase
encoded by SIRT6 gene, modulates telomeric chromatin
structure through histone deacetylation and its deple-
tion leads to abnormal telomere structure and dysfunc-
tion, end-to-end chromosomal fusions and premature
cellular senescence106.
Certain tissues with little mitotic activity, such as
liver, show progressive telomere shortening during ag-
ing, indicating that there must be factors other than cell
division which modulate the attrition of telomeres107.
Also, several external factors, such as hydrogen peroxide
and gamma radiation, cause premature senescence by in-
ducing damage throughout the genome and affect telo-
mere structure without telomere shortening107.
Sirtuins
Sirtuins (Sir, Silent Information Regulators) or class
III histone deacetylases are a gene family of NAD-de-
pendent protein deacetylases and ADP-ribosyltransfe-
rases, which are evolutionary conserved and activated
during response to stress in order to protect and stabilize
the genome. As Sirtuins are regulated by the nicoti-
namide adenine dinucleotide (NAD) cofactor and serve
as sensors of the metabolic state of the cell.
S. cerevisiae. The major genetic determinant of re-
plicative lifespan in yeast is the Sir2 gene108. An impor-
tant manifestation of the aging process in yeast is the
loss of genomic silencing at the telomeric regions and si-
lent mating-type loci (HML and HMR) which leads to
genomic instability and sterility. Silencing of the yeast
genome is carried out Sir 2,3 and 4 which form a complex
that mediates genomic silencing at HML/HMR and telo-
mere regions. Mutation which leads to overexpression of
Sir4 gene redirects the Sir 2/3/4p complex from HML/
HMR and telomeres to the nucleolus, the localization of
rDNA genes and a major site of ribosome biogenesis,
which extends lifespan by 30%108.
Overexpression of Sir2 gene increases lifespan by
50% because the Sir2 protein (Sir2p) silences chromatin,
enables DNA repair, maintaines chromosome fidelity du-
ring meiosis, mediates silencing at the rDNA region, in-
hibits rDNA recombination and also represses transcrip-
tion of inserted genes108.
Calorie restriction also activates Sir2 gene expression
which then leads to reduction in rDNA recombination109.
Polyphenol resveratrol activates sirutins and also has an-
tioxidant and anti-inflammatory properties. Resveratrol
increases replicative lifespan in yeast which indicates
that sirtuins regulate metabolism through calorie intake
and free radical production110.
Mammals. In mammals, there are seven sirtuins,
SIRT1-7, which deacetylate both histone and non-his-
tone proteins. They are involved in the regulation of gene
expression, DNA repair, apoptosis, cell cycle and insulin
regulation. Mammalian sirtuins promote longevity by
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limiting replicative lifespan and thus, protecting against
oxidative stress and cummulative DNA damage. The loss
of sirtuin expression or function bypasses replicative se-
nescence, allows cell to divide without the proper repair
of DNA which allows accumulation of mutations and in-
creases the risk of cancerogenesis111.
SIRT1 is known as the guardian against cellular oxi-
dative stress, DNA damage but is also involved in the
regulation of metabolism. The SIRT1 protein promotes
cellular survival under stress conditions by inducing
cell-cycle arrest and DNA repair through deacetylation of
p53, FOXOs, Ku70 and Nf?B112. In cultured human he-
patocytes SIRT1 deacetylates FOXO1 which promotes
transcription of gluconeogenic genes upon stress, re-
presses apoptosis and induces resistance to stress113.
Polyphenols, including resveratrol, increase SIRT1
deacetylase activity, LKB1/STK11 (serine/threonine ki-
nase 11) phosphorylation and as it has been recently
shown, the SIRT1 functions as a novel upstream regula-
tor for LKB1/AMPK signaling114.
SIRT6 is a nuclear protein with ADP-ribosyltrans-
ferase activity and is involved in the base excision repair
system (BER). SIRT6 knockout mice have a deficiency in
the BER system and show increased sensitivity to DNA
damage, chromosome aberrations and centromere dys-
function which results in global genomic instability115.
These mice die within a month after birth and show pre-
mature aging symptomes, including the loss of subcuta-
neous fat and decreased bone density.
Discussion – The Phenomenon of Aging
and Reproductive Genetics
Most of the studies on animal models have shown that
aging is inevitably related to reproduction. Genetic ma-
nipulations which extend lifespan through alterations in
metabolic pathways and stress repsonse, also reduce fer-
tility possibly to postpone reproduction until the period
of limited nutrient sources ends.
Aging is an irreversible process which involves deteri-
oration of physiological functions, loss of viability, devel-
opment of chronic diseases and cancer which result in
death. Aging is also inevitably related to decline in repro-
ductive function. Reproduction is the main determinant
of the life cycle of every species. It is estimated that up to
70% of fertilized ova are lost, making the process of hu-
man reproduction quite unsuccessful. The incidence of
unsuccessful pregnancy rises with parental, especially
mother’s age, regardless of fetal viability. In older wo-
men, oocytes show increased number of chromosomal ab-
normalities and the endometrium becomes less recep-
tive116. The majority of trisomy 21 (Down syndrome) are
caused by chromosome nondisjunction and at least 90%
of cases are due to maternal errors which occur during
oogenesis117. During aging, environmental and age-re-
lated damage accumulate in the arrested oocytes making
the increased mother’s age the most significant risk fac-
tor for chromosomal nondisjunction.
As fertility in women is directly associated with chro-
nological age, menopause could be defined as a geneti-
cally and hormonally regulated mechanism of protection
against aneuploidic concepts and against rising age-spe-
cific maternal mortality risks118. This is a possible mech-
anism by which evolution protects the human genome
against »genetic burden« which would compromise the
survival of the species. It is most likely that reproduction
is only a mechanism which allows the quality modifica-
tion, trasnmission and improvement of genetic material,
and that evolution shapes the genomes for reproductive
success and not for post-reproductive survival which en-
sures the preservation and progress of species. This is
supported by the fact that the process of aging highly
progresses in the post-reproductive period which coin-
cides with the onset of most chronic diseases, cancers
and dementias which compromises survival119. Aging
would thus be a protective mechanism which ensures re-
sources for new genetic combinations and their adapta-
tion and survival in diverse conditions.
Discussion and Conclusion
Aging and longevity are genetically regulated, but not
pre-programmed processes due to the fact that environ-
mental factors influence the rate of aging. The fact that
individuals within a species have equal lifespans sup-
ports the theory that aging is a genetically influenced
process and regardless of the fact that lifespan is contin-
uously increasing, there is a limit of human longevity
which is approximately 120 years. Thus, an organism’s
maximum lifespan potential is genetically determined
but individual variation in lifespan among individuals of
the same species indicates that the process of aging is a
consequence of an inseparable link between the genome
and environment due to the fact that external factors
constantly interact with the genome. Perhaps the most
obvious evidence comes from studies of monozygotic
twins where we would expect the same or similar process
of aging due to the fact that they share the same genetic
sequences. However, even here the singular and unique
environmental factors shape the genomes in different di-
rections, which is known as »epigenetic drift«. Studies of
twins and long-lived families suggest that approximately
20–30% of the variation in human lifespan is determined
by genetic factors, which becomes more important for
survival at old age120.
From an evolutionary perspective, aging limits the re-
productive potential and as such should be opposed by
natural selection and thus, most gerontologists believe
that there are no genes which cause aging. The fact that
»longevity genes« or »gerontogenes« have not yet been
found could be explained by the fact that aging is proba-
bly a physiological process which normally follows em-
bryonic and postnatal development and genes regulating
these processes also probably control aging.
Series of studies have demonstrated that age-related
diseases take root in early nutrition, during gestation
and lactation which is known as »fetal programming«. It
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is well known that low birthweight and short body length
at birth are associated with increased risk of developing
cardiovascular disease, obesity and type 2 diabetes in
adult life. The fetal programming hypothesis proposes
that these diseases originate through adaptation which
the fetus makes when it is undernourished and the func-
tions which are set prenatally determine the function
and the structure of the body in adult life. The link be-
tween fetal growth and age-related diseases involve ex-
tensive changes in gene expression, which makes the
epigenetic modifications one of the most important regu-
lators of the aging process.
As shown in this review, most of what we know on the
process of aging in humans comes from animal models,
human cells and human premature aging syndromes.
The existence of genes which influence lifespan in vari-
ous species points to the fact that aging is an evolution-
ary conserved process. All of the genes so far identified as
longevity genes are involved in stress resistance, meta-
bolic pathways and maintenance of genomic integrity. In
humans, the susceptibility genes for certain diseases also
influence the aging process. The importance of genes in-
volved in cardiovascular diseases seem to be a crucial de-
terminant of human longevity since they represent the
primary cause of death in the modern world. For exam-
ple, certain apolipoprotein E genotypes influence life-
span through association with disease. Other proposed
candidate genes might involve metabolic genes, immu-
ne-system genes, mtDNA mutations, DNA repair system
genes and genes regulating telomere length – the genes
whose function clearly declines and changes later in
life121. Single nucleotide polymorphisms (SNP) are the
most common type of genetic variations and can deter-
mine changes in gene expression which can be a factor of
susceptibility to various diseaseas and even aging. The
research on SNPs in long-lived humans might lead to dis-
covery of gene candidates associated with aging. As telo-
mere lenght and epigenetic modifications are heritable,
it could be possible that genetic variations between indi-
viduals, which affect telomere structure and epigenetic
modifications, are important determinants of longevity
and development of different age-related diseases.
The genome is an extremely dynamic structure. Throu-
ghout life, epigenetic modifications are not fixed, but are
constantly changing in response to environmental stim-
uli which modulates gene expression. Environmental
conditions in which the genome is set play an exceptional
role in the modification and regulation of developmental
processes. As it has been recently stated, the physiologi-
cal hypoxia of the first trimester gestational sac may pro-
tect the developing fetus against the deleterious and
teratogenic effects of reactive oxygen species122. On the
other hand, excessive production of ROS during later
stages of development gradually damages the cell and
leads to loss of function and cell viability. This indicates
that aging is a part of normal ontogenesis and is the con-
sequence of the »communication« between the genome
and environment and extensive and continuous genetic/
epigenetic changes. Alterations in DNA methylation pat-
tern and progressive telomere shortening during aging
represent a genetically determined »post-embryonic co-
unting« mechanism, a »time-bomb« which is set after
fertilization and dictates lifespan thereafter. Thus, fu-
ture studies on epigenetic mechanisms and their dy-
namic changes through lifetime might provide key an-
swers to many questions related to aging.
Researches which regard aging only as a pathophysi-
ological mechanism will not provide answers. As aging is
a multidimensional process of genetic, physical, psycho-
logical, and social changes, the complete understanding
of aging mechanisms will be possible only through an in-
tegrative approach.
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GENETI^KI I EPIGENETI^KI POGLED NA PROCES STARENJA U ^OVJEKA
S A @ E T A K
Proces starenja je jedan od najslo`enijih i najintrigantnijih biolo{kih fenomena. Starenje je geneti~ki reguliran pro-
ces u kojem je maksimalni `ivotni vijek organizama predodre|en, dok brzina starenja ovisi o okoli{nim ~imbenicima i
`ivotnom stilu. S obzirom na slo`enost mehanizama uklju~enih u regulaciju procesa starenja, do danas ne postoji jedin-
stvena, sveobuhvatna teorija koja ih mo`e objasniti. Kako geneti~ki/epigeneti~ki, kao i okoli{ni ~imbenici neizbje`no
utje~u na proces starenja, ovdje donosimo pregled geneti~ke i epigeneti~ke regulacije najva`nijih molekularnih i stani-
~nih mehanizama uklju~enih u proces starenja. Tako|er dajemo pregled klju~nih geneti~kih i molekularnih puteva
povezanih sa starenjem, temeljenih na istra`ivanju oksidativnog stresa, metabolizma, genomske stabilnosti, epigene-
ti~kih modifikacija i stani~nog starenja u `ivotinjskim modelima i ~ovjeka. Kako ve}ina geneti~kih modifikacija koje
utje~u na proces starenja istovremeno utje~u i na reprodukciju u ~ovjeka, raspravljamo o starenju kao postreprodu-
ktivnom geneti~ki odre|enom procesu. Nakon reprodukcije starenje ubrzano napreduje {to se klini~ki podudara sa
nastupom ve}ine kroni~nih bolesti, tumora i demencija. Kako evolucija oblikuje genome za reproduktivni uspjeh a ne za
postreproduktivno pre`ivljenje, starenje se mo`e definirati kao za{titni mehanizam koji osigurava o~uvanje i napredak
vrste kroz kvalitetnu modifikaciju, preno{enje i pobolj{anje geneti~kog materijala.
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